Medical Device Global Market Access

This episode demystifies the medical device approval process in the United Arab Emirates. We explain the central role of the Ministry of Health and Prevention (MOHAP), the mandatory manufacturer registration, and how the formal risk-based classification system (Classes I-IV) dictates your entire path to market, from evidence requirements to review timelines. Key Questions: • Who is the single regulatory authority for medical devices in the UAE? • What is the first step a manufacturer must take before submitting a product for approval? • How does the UAE classify medical devices based on risk? • Why is receiving a formal risk classification from MOHAP so critical for your submission strategy? • What does your device's classification determine about your evidence and documentation requirements? • How do international approvals like CE marking influence the UAE process? • What is the typical validity period for a medical device registration certificate in the UAE? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the mandatory requirement for a Local Authorized Representative (LAR) when bringing a medical device to the United Arab Emirates market. We explore the critical functions of the LAR as the interface with the Ministry of Health and Prevention (MOHAP), their legal responsibilities for product registration and post-market vigilance, and the strategic importance of selecting an independent representative over a commercial distributor. Key Questions: • Is a local representative mandatory for selling medical devices in the UAE? • What are the core responsibilities of a Local Authorized Representative (LAR)? • Who legally holds the medical device registration license in the UAE? • How does an LAR interact with the UAE's Ministry of Health and Prevention (MOHAP)? • What is the LAR's role in post-market surveillance, vigilance, and recalls? • What are the risks of appointing a commercial distributor as your authorized representative? • Why is selecting an LAR a critical strategic decision for market access and control? • Can you change distributors if your device registration is held by them? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode breaks down the essential documentation required for medical device registration with the UAE's Ministry of Health and Prevention (MOHAP). We explore the complete technical dossier, from the Free Sale Certificate and ISO 13485 to bilingual labeling and clinical data. A key focus is clarifying the "simplified pathway" for devices with prior CE or FDA approval, explaining how it impacts the review process without reducing the amount of paperwork required for a successful submission. Key Questions: • What is the UAE's key regulatory authority for medical devices? • What core documents are required in a MOHAP technical dossier? • Do device labels and instructions need to be in Arabic? • Can a prior CE Mark or FDA clearance get you to the UAE market faster? • What does the "simplified pathway" for MOHAP registration really mean? • Do you still need to submit a full technical file even with prior FDA/CE approval? • Why is robust clinical and risk data non-negotiable for the UAE? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the landmark changes introduced by the UAE's Federal Decree-Law 38 of 2024, which took effect on January 2, 2025. We explore the creation of the new Emirates Drug Establishment (EDE), the critical new requirements for importers and distributors, and what the one-year grace period means for medical device manufacturers looking to enter or remain in the UAE market. • What is the new Federal Decree-Law 38 of 2024 and when does it become effective? • How does the new Emirates Drug Establishment (EDE) change the regulatory landscape in the UAE? • What specific new rules apply to Marketing Authorisation Holders regarding importers and distributors? • Are both pharmaceuticals and medical devices now governed by the same law? • How long is the grace period for companies to comply with the new regulations? • What key areas, like contracts and quality systems, must be updated before the January 2, 2026 deadline? • Why is the UAE making these significant changes to its regulatory framework? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode provides a detailed breakdown of the timelines and costs associated with registering a medical device in the United Arab Emirates. We explore the two main regulatory pathways, the specific government fees in AED, and the often-overlooked indirect costs like translation and notarization that manufacturers must budget for. We also break down the review timelines based on MOHAP’s risk classification system. Key Questions: • What is the first step for any manufacturer entering the UAE market? • How does the device risk class affect the MOHAP review timeline? • What are the specific government fees in Emirati Dirhams for device registration? • Are there different regulatory pathways for professional-use versus home-use devices? • What are the "hidden costs" that can impact your budget? • How long is a medical device registration certificate valid for in the UAE? • Who is the primary regulatory authority for medical devices in the UAE? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode dives into the critical components of medical device distributor agreements that protect manufacturers from underperformance. We explore how to structure contracts with specific Key Performance Indicators (KPIs) and robust termination clauses, turning your agreement into a tool for accountability and market success, rather than a liability. • How can an exclusive distributor agreement backfire and trap your product? • What are the most effective KPIs to include beyond simple sales numbers? • Why should you define targets for marketing spend and demo placements? • What specific performance failures should trigger a termination clause? • How can you structure a termination clause that is both fair and firm? • What is a "cure period" and why is it essential for a healthy partnership? • How do you ensure your distributor's sales team is properly trained and certified? • What other triggers, like insolvency, should be included in your agreement? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

A successful product launch goes far beyond the initial sale. For manufacturers of high-complexity analyzers and consumables, the true test of a distribution partner lies in their logistical prowess and service support infrastructure. This episode explores the essential, non-negotiable support functions that ensure your device not only reaches the customer but operates reliably to meet the demanding uptime requirements of modern clinical laboratories. Key Questions: • Does your distribution strategy account for the entire product lifecycle? • How vital is unbroken cold-chain logistics for your reagents and consumables? • What does on-site installation and performance validation truly entail for complex instruments? • Can your support network provide immediate, 24-hour technical assistance to a lab in crisis? • Is your distributor equipped with the warehousing and field-service engineers needed to guarantee nationwide uptime? • How quickly can you deliver critical replacement parts to any clinical lab? • Are you prepared to meet the stringent uptime and quality standards mandated by regulations like the Clinical Laboratory Improvement Amendments (CLIA) of 1988? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode demystifies the distinct and critical roles of the FDA U.S. Agent and the Initial Importer for medical device manufacturers entering the U.S. market. We explore the specific regulatory responsibilities of each, highlighting why appointing a distributor without proven compliance expertise can jeopardize your import success and post-market standing. • What is the fundamental difference between an FDA U.S. Agent and an Initial Importer? • Who is legally responsible for reporting adverse device events to the FDA? • Can your distributor also act as your Initial Importer? • What are the risks of choosing an Initial Importer without proven regulatory processes? • Which entity is responsible for verifying a device's 510(k) or PMA status upon import? • How do these roles directly impact whether your shipments clear U.S. customs? • What specific post-market surveillance duties does an Initial Importer have? • Why is this distinction crucial for maintaining compliance once your device is in the U.S. market? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

Choosing the right U.S. distributor is a make-or-break decision for IVD manufacturers. This episode moves beyond big names to focus on the critical importance of aligning with a distributor's specific customer focus and sales structure. We explore why understanding "call points"—whether in hospital labs, reference labs, or physician offices—and ensuring a distributor will dedicate resources to champion your new device are non-negotiable steps for a successful market launch. • What are "call points" and why do they determine your product's success? • Is your potential distributor a strategic partner or just a logistics provider? • How can you ensure your new IVD device won't get lost in a massive product catalog? • Will a distributor allocate dedicated sales reps to champion your new technology? • What tough questions must you ask a distributor before signing any agreement? • Does the distributor's existing portfolio create a conflict of interest for your product? • How do you identify a partner who is genuinely invested in your growth in the U.S. market? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

Securing a U.S. medical device code is only half the battle; the next challenge is determining its payment rate. This episode breaks down the three primary pathways for setting reimbursement rates in the United States. We explore the roles of CMS and private payers, detailing the specifics of the cross-walking and gap-filling processes, including key timelines like the annual summer public meetings. We also uncover the most common pitfalls that can delay or diminish your device's earning potential, from unfavorable comparisons to the complexities of negotiating with hundreds of individual payers. Key Questions: * Once a device has a code, how is its reimbursement rate actually set? * What is CMS's "cross-walk" process, and what are its biggest risks? * How does "gap-filling" work for novel technologies without a comparator? * What is the typical timeline for the gap-fill process and when do key decisions happen? * How do private payers determine payment rates, and how does it differ from Medicare? * What are the most common pitfalls that can undervalue a new medical device? * Why is the first year of a new code often financially unpredictable? * How can you build a strategy to navigate both CMS and private payer negotiations? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

Navigating the FDA's import regulations requires a clear understanding of two critical, yet distinct, roles: the U.S. Agent and the Initial Importer. This episode breaks down their specific responsibilities, explaining how confusing them can lead to costly customs delays and compliance failures. We explore the specific regulatory burdens of the Initial Importer, including Medical Device Reporting and device listing, and highlight why manufacturers must verify their distributor’s capabilities to ensure smooth market entry. • What is the fundamental difference between an FDA U.S. Agent and an Initial Importer? • Why is the U.S. Agent's role primarily administrative and not related to compliance? • What specific regulatory responsibilities, like MDR, does an Initial Importer handle? • How can selecting the wrong Initial Importer halt your device shipments at the border? • What are the most common errors in entry filings related to import roles? • How do you verify if your distributor is truly ready to act as your Initial Importer? • What post-market surveillance duties fall on the Initial Importer? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

Securing shelf space is just the beginning; ensuring your medical device is billable is the key to commercial success. This episode explores the crucial role a distributor plays in navigating the complex reimbursement landscape. We discuss how a strategic partner’s “contracting muscle” can manage interim billing codes, overcome Medicare edits, and leverage powerful GPO contracts to accelerate market adoption and ensure your innovation gets paid. Key Questions: • Why is a distributor’s reimbursement expertise as important as their logistics network? • What are interim billing routes, and how do they enable early product adoption? • How can a distributor help a new assay navigate miscellaneous CPT codes without triggering denials? • What role do Medicare Part B edits play in the payment process? • How do Group Purchasing Organizations (GPOs) accelerate market access? • Why are a distributor’s existing GPO contracts a critical asset for a new device launch? • How does a distributor’s “contracting muscle” directly impact your revenue and market share? • What should you look for in a distributor beyond their warehouse and shipping capabilities? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

Beyond regulatory approval, the success of high-complexity medical devices hinges on a robust support infrastructure. This episode explores the critical, often-overlooked challenges of logistics, installation, and service. We delve into why cold-chain management, on-site validation, and 24/7 technical support are non-negotiable for devices like advanced analyzers and their sensitive consumables, particularly in meeting stringent lab requirements. Key Questions: • What are the hidden logistical hurdles for high-complexity analyzers? • How does cold-chain management directly impact your product's viability and lab results? • Is your distributor truly equipped for specialized on-site installation and validation? • Can your support network meet the 24-hour uptime demands of a CLIA-certified lab? • How can you guarantee rapid access to replacement parts across an entire country? • Does your partner have a deployable network of skilled field-service engineers? • Are you evaluating your distributor's warehousing capabilities as rigorously as their sales team? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

Granting distributor exclusivity can be a powerful market entry tool, but it carries significant risks if not managed correctly. This episode explores how to structure robust distribution agreements by embedding specific Key Performance Indicators (KPIs) and strategic termination clauses to ensure accountability and protect your interests. We delve into the essential metrics and contractual safeguards that can make the difference between a thriving partnership and a costly mistake. • Is an exclusive distributor agreement a golden ticket or a golden cage? • What specific Key Performance Indicators (KPIs) must be in every MedTech distribution contract? • How can you hold your distributor accountable for sales quotas and marketing spend? • What is the critical difference between "termination for cause" and "termination for convenience"? • Why might a "no-fault" termination clause be your most important contractual safeguard? • How do you structure an agreement to prevent being locked in with an underperforming partner? • What reporting requirements should you demand from your international distributors? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

Choosing the right U.S. distributor is a make-or-break decision for IVD manufacturers. This episode explores why customer fit and sales focus are more critical than size. We dissect the importance of matching a distributor’s call-points—be it hospital labs, reference labs, or physician offices—to your specific device and how to ensure your product becomes a priority for their sales team, rather than getting lost in a crowded catalog. • Why is a distributor's existing customer base the most important factor for your success? • What are "call-points" and how do they differ between hospital, reference, and physician-office labs? • How can you determine if a potential distributor truly serves your target market? • Is there a risk of your new IVD device getting ignored in a large distributor's catalog? • What specific questions must you ask a distributor before signing an agreement? • How do you verify that a distributor will dedicate sales resources to champion your product? • Does a larger distributor automatically mean better market access? • How do you turn a distributor into a strategic partner for your U.S. market entry? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode breaks down the critical differences in securing reimbursement for In-Vitro Diagnostics (IVDs) between the European Union's national HTA bodies and the payer-driven system in the United States. We explore the specific requirements of key European agencies like Germany's G-BA and France's HAS and contrast them with the evidence demanded by CMS and private insurers in the U.S. Key Questions: • Is there a single reimbursement pathway for an IVD in the European Union? • Which national bodies decide if your IVD gets reimbursed in Germany and France? • How did the 2011 AMNOG act in Germany change evidentiary standards? • What are the core differences between the evidence required by EU HTA bodies and U.S. payers? • How does the role of CMS in the U.S. compare to that of a national HTA agency in Europe? • Why is demonstrating economic value just as important as clinical utility in the American market? • What are Local and National Coverage Determinations (LCDs/NCDs) in the U.S.? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode breaks down the complex process of how the U.S. Centers for Medicare & Medicaid Services (CMS) decides whether to cover a new in-vitro diagnostic (IVD) test. We explore the critical "reasonable and necessary" standard, the difference between National and Local Coverage Determinations, and the vital role of clinical utility evidence in securing a positive decision. Learn about the specific frameworks CMS uses and the specialized programs in place for advanced diagnostics. Key Questions • What is the single most important principle Medicare uses to evaluate a new diagnostic test for coverage? • How do National Coverage Determinations (NCDs) differ from Local Coverage Determinations (LCDs)? • Why does CMS prioritize clinical utility over clinical validity? • What specific evidence framework does CMS use to assess if a test improves patient outcomes? • What is the MolDX program, and how does it impact molecular diagnostic tests? • Why is having data generalizable to the Medicare population so critical for a successful submission? • How does the FDA's final rule on LDTs from May 2024 affect the path to market? • What level of evidence is needed to prove a test is "reasonable and necessary"? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the critical post-market data strategies required to secure and defend reimbursement for innovative in-vitro diagnostics (IVDs). We explore the distinct evidence that persuades U.S. insurers versus EU payers, moving beyond initial regulatory approval to focus on long-term value demonstration. Learn about the types of real-world evidence, registry studies, and economic data that are most effective for renegotiating coverage and justifying premium pricing in these key global markets. • What type of real-world evidence is most convincing to a U.S. insurer? • How do the data requirements of EU HTA bodies differ from U.S. payers? • Is a registry study or an economic analysis more powerful for defending price? • How does the EU's In-Vitro Diagnostic Regulation (IVDR) of May 2022 impact payer evidence requirements? • What is "clinical utility" and why is it essential for reimbursement negotiations? • How can you design a post-market study to demonstrate direct budget impact? • When should you begin planning your post-market data collection strategy? • Why is U.S.-specific claims data so persuasive for American payers? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode details the process of obtaining a unique CPT or PLA code for a diagnostic assay in the U.S. and its direct impact on reimbursement under the Medicare Clinical Laboratory Fee Schedule (CLFS). We cover the application steps with the American Medical Association (AMA), the role of the PAMA Act, and recent legislative updates affecting payment rates and reporting deadlines. • What is a Proprietary Laboratory Analyses (PLA) code and why is it crucial for my new assay? • What is the step-by-step process for submitting a PLA code application to the AMA? • Who are the CPT Editorial Panel and the PLA-TAG, and what role do they play? • What are the key deadlines and timelines I need to be aware of, including the September 9, 2025 application deadline? • How does the Protecting Access to Medicare Act (PAMA) of 2014 influence my test's payment rate? • What is the Clinical Laboratory Fee Schedule (CLFS) and how are rates determined? • How did the legislation on September 26, 2024, change the data reporting requirements and payment reductions? • What is the next data reporting period and what data collection period is it based on? • How does having a unique PLA code ultimately lead to a specific payment rate for my assay? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode demystifies the critical process of authenticating FDA export documents, such as the Certificate to Foreign Government (FSC/CFG), for international markets. We explore the difference between an apostille and full legalization, explain why foreign regulators require this step, and detail the impact of the FDA's transition to electronic certificates as of January 2, 2024. Learn the new rules and procedures to ensure your medical device shipments aren't delayed at the border. Key Questions: • What is the difference between an apostille and legalization? • Which countries require an apostille for my Certificate to Foreign Government? • How did the FDA's switch to electronic certificates on January 2, 2024, change the process? • Why do I need to print my electronic certificate in color? • What is the FDA's new QR code validation system (FECV)? • Does the new FDA validator replace the need for an apostille? • What is the multi-step process for countries not part of the Hague Convention? • Who issues the apostille for federal documents in the United States? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode provides a detailed guide on the essential supporting documents required for a Free Sales Certificate (FSC) application. We break down the specific requirements based on medical device classification under the EU MDR, clarifying which documents, such as the Declaration of Conformity, ISO 13485, and CE certificates, are necessary for Class I, IIa, IIb, and III devices. Understand the critical differences in documentation to ensure your export applications are successful. Key Questions: • What is a Free Sales Certificate and why is it vital for exporting medical devices? • Which two documents are fundamental to nearly every FSC application, regardless of class? • Is a Notified Body CE Certificate a mandatory submission for all device classes? • How do the documentation requirements for a Class I device differ from a Class IIb or III device? • What specific proof of a Quality Management System do authorities expect? • Can a certificate from the old Medical Device Directive (MDD) still be used for an FSC application today? • Which government body is responsible for issuing the FSC? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

In this episode, we demystify the Free Sales Certificate (FSC), a critical document for medical device and IVD manufacturers aiming for international expansion. We explore what an FSC is, why it's a mandatory requirement for registration in many countries across Asia, Latin America, and the Middle East, and how it serves as proof of regulatory compliance in your home market. The host explains who issues these certificates in key regions like the EU and the US, and discusses recent changes under the EU MDR that impact all manufacturers. Key Questions: • What is a Free Sales Certificate and why is it essential for exporting medical devices? • How does an FSC accelerate market entry in foreign countries? • Which global regions most commonly demand an FSC for product registration? • What is the difference between an FSC from the EU and a CFG from the US FDA? • Who is responsible for obtaining an FSC for a non-EU manufacturer? • How has the EU's Medical Device Regulation (MDR) impacted the FSC application process? • Can legacy devices still use old certificate formats? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode demystifies the process of obtaining a Certificate to Foreign Government (CFG), also known as a Free Sale Certificate (FSC), from the US FDA. We cover the official timelines for issuance, the specific government fees you can expect to pay, and the critical procedural shift to electronic-only certificates that took effect in early 2024. Learn the essential details to plan your international market submissions effectively and avoid costly delays. • What is the official FDA term for a “Free Sale Certificate”? • How long does the FDA have to issue an export certificate once requested? • What is the exact government fee for the first CFG? • How much does each additional certificate from the same request cost? • Is there a page limit that could unexpectedly increase your fees? • What major change did the FDA implement for all export certificates on January 2, 2024? • How can foreign governments now instantly authenticate your certificate? • Why is this certificate a mandatory requirement for market entry in many regions? • How can you efficiently manage product lists to control costs? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode clarifies the complex eligibility requirements for obtaining a Certificate of Free Sale (FSC) for medical device exports. We dissect the critical differences between the regulatory frameworks in the United States and the European Union, explaining precisely who—from manufacturer to exporter to authorized representative—can legally apply for this essential market access document in each region. Key Questions: • What is a Certificate of Free Sale (FSC) and why do exporters need it? • In the United States, can a distributor or exporter apply directly for an FDA Certificate to Foreign Government (CFG)? • Under the EU's Medical Device Regulation (MDR), who is legally permitted to request a Certificate of Free Sale? • Why are importers and distributors explicitly ineligible to apply for an FSC in Europe? • What is the critical role of an EU Authorized Representative in the FSC application process for non-EU companies? • How did the FDA's process for issuing export certificates change as of January 2024? • What is the key difference between who can apply for an FSC in the US versus the EU? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

Many companies believe that getting medical device approval in Japan might fast-track their entry into the U.S. market. This episode breaks down that misconception and reveals the strategic pathway that actually exists. We explore how the FDA’s Abbreviated 510(k) program allows manufacturers to leverage their existing PMDA data, focusing on the crucial role of internationally recognized consensus standards. Learn how this approach can save significant time and resources compared to a traditional submission, without compromising regulatory diligence. Key Questions: • Is there a direct reciprocity agreement between Japan's PMDA and the US FDA for device approvals? • How does an Abbreviated 510(k) submission differ from a Traditional one? • What are "recognized consensus standards," and why are they the key to this strategy? • Can I reuse testing data for biocompatibility and electrical safety from my Japanese submission for the FDA? • What is the Safety and Performance Based Pathway, and how is it related? • Does using the Abbreviated 510(k) program eliminate the need for a predicate device? • How can a declaration of conformity simplify the FDA review process? • What is the most important first step to leveraging a PMDA certification for FDA clearance? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode clarifies whether a medical device approved by China's NMPA can benefit from an expedited registration process with Brazil's ANVISA. We detail the full Brazilian regulatory requirements, including classification, the role of a Brazil Registration Holder (BRH), B-GMP certification, and the AREE program, explaining why NMPA approval doesn't currently offer a shortcut. • Can my Chinese NMPA approval speed up device registration in Brazil? • What is the AREE program, and which countries does ANVISA recognize for faster review? • What are the two main registration pathways for medical devices in Brazil? • Why is a Brazilian Registration Holder (BRH) mandatory for foreign manufacturers? • Do all medical devices require a Brazilian Good Manufacturing Practice (B-GMP) certificate? • What is the key regulation that governs medical device classification and registration in Brazil? • What are INMETRO and ANATEL certifications, and when are they required? • What is the difference between the *Notificação* and *Registro* pathways? • Does having MDSAP certification replace the need for a B-GMP audit? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode tackles a common question from MedTech manufacturers: can a successful ANVISA registration in Brazil streamline the path to FDA 510(k) clearance in the United States? We explore the reality of regulatory reliance between these two key markets, clarifying the one-way nature of current frameworks and outlining how your existing ANVISA technical documentation can still provide a significant advantage for your US submission. • Does the FDA recognize or have a reliance pathway for ANVISA-approved medical devices? • What is Brazil's new "Reliance" program (IN 290/2024) and how does it affect US manufacturers? • Can the technical dossier created for ANVISA be used for an FDA 510(k) submission? • What are the fundamental differences between an ANVISA registration and an FDA 510(k)? • How does the concept of a "predicate device" make the 510(k) process unique? • Can my BGMP (Brazilian Good Manufacturing Practices) certification help with FDA QSR compliance? • What parts of my ANVISA submission, like clinical data and risk analysis, can be repurposed? • What are the critical gaps I need to fill when moving from a Brazilian approval to a US submission? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode breaks down the essential differences between China's NMPA approval and the EU's rigorous MDR CE marking process. We explore the key gaps in regulatory philosophy, clinical data requirements, and post-market surveillance that manufacturers must bridge to expand from the Chinese to the European market. Key Questions: • Is my NMPA approval enough to get a CE mark in Europe? • What is the difference between a Notified Body and the NMPA? • How do EU MDR requirements for a Clinical Evaluation Report (CER) differ from China's? • Why is Post-Market Surveillance (PMS) more demanding under the EU MDR? • What is a Person Responsible for Regulatory Compliance (PRRC) and do I need one? • How does the approach to the Quality Management System (QMS) vary between the two regions? • Can I reuse my technical documentation from China for my EU submission? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

Securing Shonin approval in Japan is a huge regulatory achievement, but it doesn’t guarantee a simple path to the European market. This episode breaks down the key differences between Japan's PMD Act and the EU's demanding Medical Device Regulation (MDR). We explore the critical gaps manufacturers must address in their Quality Management System, technical documentation, clinical evidence, and post-market surveillance strategies to successfully obtain a CE Mark. Key Questions: • Can I reuse my Japanese technical documentation for my CE Mark application? • Why is the EU's Clinical Evaluation Report (CER) more demanding than Japanese requirements? • What is a Periodic Safety Update Report (PSUR) and do I need one for Europe? • How does a Japanese Marketing Authorization Holder (MAH) differ from an EU Authorised Representative? • Is my Japanese QMS automatically compliant with EU standards? • What are the biggest hurdles when moving from the Japanese market to the EU? • Does Shonin approval shorten the timeline for getting an EU CE Mark? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode details the process for medical device manufacturers to obtain FDA 510(k) clearance in the United States after securing Class III approval from China's NMPA. We explain that there is no direct reciprocity and outline how to strategically leverage existing Chinese technical documentation, clinical data, and testing reports. The focus is on conducting a thorough gap analysis to meet the FDA's unique requirements, particularly the concept of "substantial equivalence" to a predicate device and compliance with 21 CFR Part 820 for quality management systems. • Does my NMPA Class III approval guarantee FDA clearance? • How can I use my clinical trial data from China for an FDA submission? • What is a "predicate device" and why is it crucial for a 510(k)? • Do I need to repeat all my device testing for the U.S. market? • What are the key differences between China's GMP and the FDA's Quality System Regulation? • What is a gap analysis and why is it the most critical step? • Is it mandatory to submit my 510(k) electronically? • What is a U.S. Agent and do I need to have one? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode breaks down the process of using your existing European CE Marking to register a medical device in Australia. We cover the essential role of Manufacturer's Evidence, the TGA's application process and timelines, potential audits, and the latest on fees and charges, providing a clear roadmap for MedTech companies looking to enter the Australian market. Key Questions: • What is "Manufacturer's Evidence" and why is it the key to TGA approval? • How does my EU device classification translate to the Australian system? • Can I still use a legacy MDD certificate for a new TGA application? • What recent changes affect high-risk Class III and IVD devices? • What are the typical timelines for a TGA review based on a CE mark? • Is my device guaranteed to be audited by the TGA? • How much does a TGA application cost, and have fees changed recently? • What is an Australian Sponsor and why do I need one? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide, including TGA submissions and Australian Sponsor services. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode explores how medical device manufacturers can effectively use their existing CE mark clinical data for an FDA De Novo submission for a novel technology. We delve into the FDA's expectations for foreign data, common gaps between EU and US requirements, and the strategic importance of the Pre-Submission program to de-risk market entry. • Can you directly use your CE mark clinical study for an FDA De Novo submission? • What are the most common data gaps the FDA identifies in European studies? • How does the FDA's view on patient demographics differ from European regulators? • Why might the standard of care in your EU study be a problem for the FDA? • Is a US-based clinical trial always necessary if you already have CE mark data? • What is a "bridging study" and when might you need one? • How can a Pre-Submission meeting with the FDA save you time and money? • What key FDA guidance from April 2015 governs the use of foreign clinical data? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

Navigating Japan's rigorous PMDA approval process can be challenging, even for devices that already have a CE mark. This episode demystifies the requirements for a Shonin application, explaining how manufacturers can leverage their existing CE mark data. We break down the critical differences and synergies between the EU and Japanese regulatory systems, from Quality Management Systems and technical documentation to the all-important clinical data requirements and the mandatory role of a local Marketing Authorization Holder (MAH). Key Questions: • Does a CE mark guarantee PMDA approval in Japan? • Can my ISO 13485 certificate satisfy Japan's QMS requirements under MHLW Ordinance No. 169? • What is the STED (Summary Technical Documentation) and how does it differ from my EU Technical File? • Must all documentation be submitted in Japanese? • Will my European clinical data and CER be accepted by the PMDA? • What are the common reasons the PMDA might require a new clinical trial in Japan? • What is a Marketing Authorization Holder (MAH) and why is one essential for market entry? • How does the Medical Device Single Audit Program (MDSAP) affect the process? • What were the key changes in the March 2024 QMS compliance deadline? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode demystifies the process for manufacturers who have an EU CE mark under the MDR and are seeking FDA 510(k) clearance. We break down the crucial differences and similarities between the two regulatory systems, explaining how to leverage existing technical documentation and what new requirements and strategic considerations, like selecting a predicate device, you will face when entering the United States market. Key Questions: • Does an EU CE mark give my device an advantage with the FDA? • What is "Substantial Equivalence" and why is it crucial for a 510(k)? • How can I reuse my MDR technical documentation for an FDA submission? • What are the key differences between EU and US quality system requirements? • Is my ISO 13485 certification enough for the FDA? • What is the mandatory eSTAR format for 510(k) submissions that started on October 1, 2023? • Why do I need to appoint a US Agent? • What are the biggest gaps between a CE technical file and a 510(k) submission? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode demystifies the process of bringing a CE-marked medical device to the Brazilian market. We break down the critical differences between European requirements and Brazil's ANVISA regulations, focusing on the essential documentation, testing, and certification gaps that manufacturers must address for successful registration. • Is a CE mark enough to sell your medical device in Brazil? • What is a Brazil Registration Holder (BRH) and why is it mandatory? • How does ANVISA's technical dossier differ from a European Technical File? • Can an MDSAP certificate replace the need for an ANVISA factory inspection? • What is INMETRO certification and does my electrical device require it? • Are my existing ISO 10993 biocompatibility test reports valid for Brazil? • How has the new RDC 751/2022 regulation changed the registration process? • What are the strict translation requirements for ANVISA submissions? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode details the strategic process for transitioning a medical device with a European CE mark under MDR to achieve Class II or III registration with China's NMPA. We break down the unique requirements, from local representation to in-country testing and clinical evaluation pathways, providing a clear roadmap for manufacturers looking to enter the complex but lucrative Chinese market. Key Questions: • Is a CE mark sufficient for selling a medical device in China? • What is a Product Technical Requirement (PTR) and why is it essential for NMPA registration? • Can we use our existing EU clinical data for the Chinese submission? • What are the mandatory in-country testing requirements in China? • How long does the NMPA approval process typically take for Class II and III devices? • What is the role of a mandatory China Agent in the registration process? • Can our device qualify for an exemption from clinical trials in China? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode demystifies the process for CE-marked device manufacturers to obtain a Health Canada Medical Device Establishment Licence (MDEL) for selling in Canada. We break down the crucial differences between an MDEL and a product-specific Medical Device Licence (MDL), clarify who needs to hold an MDEL, and explain why having a CE mark is not a substitute for this essential Canadian requirement. Learn about the key procedural documentation needed for a successful application and the latest guidance from Health Canada. Key Questions: • What is a Health Canada MDEL and how does it differ from an MDL? • If our device has a CE mark, do we still need an MDEL to sell in Canada? • Who is legally required to hold an MDEL? • Can a foreign manufacturer or distributor apply for an MDEL directly? • What are the core procedural requirements for a successful MDEL application? • How does the new GUI-0016 guidance, effective December 2024, impact applicants? • Does having an MDSAP certificate exempt a company from needing an MDEL? • What activities are covered by a Medical Device Establishment Licence? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode breaks down the essential steps for medical device manufacturers with a CE mark to comply with UK regulations for Great Britain. We cover the extended deadlines for CE mark recognition, the immediate requirements for MHRA registration and appointing a UK Responsible Person (UKRP), and the process for achieving UKCA conformity assessment. Learn the key dates and actions you need to take to ensure uninterrupted market access. Key Questions: • Is my CE mark still valid for selling medical devices in Great Britain? • What are the new deadlines for transitioning from CE to UKCA marking? • Do I need to switch to the UKCA mark immediately? • What is a UK Responsible Person (UKRP) and do I need one? • What is the first step I must take to place my device on the UK market? • How does the UKCA conformity assessment process differ from the CE marking process? • Are my existing CE technical files useful for the UKCA mark? • What are the specific labelling requirements for the UKCA mark? • Do the same rules apply to Northern Ireland? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode provides a focused guide to Japan's medical device regulations. We explore the relationship between the overarching PMD Act and the detailed QMS requirements of MHLW Ordinance 169. Learn about the crucial 2021 harmonization with ISO 13485:2016, the key differences that remain, and how the Japanese audit process presents unique challenges for foreign manufacturers, including an expanded audit scope and specific documentation demands. Key Questions: • What is the relationship between Japan's PMD Act and MHLW Ordinance 169? • Is my ISO 13485:2016 certification enough to sell my medical device in Japan? • What are the key "gaps" between Japan's QMS requirements and ISO 13485? • How has the March 25, 2024, deadline impacted QMS compliance for Japan? • What is a "Medical Device File" and how does it differ from an EU Technical File? • Who gets audited during a Japanese QMS conformity assessment? • What are the specific document and record retention rules under Ordinance 169? • Why is the Marketing Authorization Holder (MAH) so vital for regulatory success in Japan? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode delves into the landmark revision of China's medical device regulations, State Council Order No. 739, which took effect on June 1, 2021. We break down the critical changes impacting global MedTech manufacturers, from the revolutionary Marketing Authorization Holder (MAH) system to new clinical evaluation pathways and heightened post-market responsibilities. Key Questions: • What is the new Marketing Authorization Holder (MAH) system and how does it change liability? • Can you now use your own company's testing data for NMPA submissions? • What are the new pathways for conditional or expedited approval in China? • How have clinical evaluation requirements been relaxed for certain devices? • What are the increased penalties for non-compliance under Order 739? • Why is the Unique Device Identification (UDI) system critical for post-market surveillance? • How does Order 739 impact foreign manufacturers specifically? • What new responsibilities do legal representatives and senior management now face? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode provides a deep dive into India's Medical Device Rules, 2017, and the subsequent amendments through 2023. We explore the shift to a risk-based classification system, new Quality Management System (QMS) and licensing requirements, and the critical role of the Central Drugs Standard Control Organization (CDSCO). The discussion covers practical implications for manufacturers, including post-market surveillance, vigilance, and the latest 2023 updates to the regulatory framework. • What were the landmark changes introduced by the Medical Device Rules, 2017? • How does India's risk-based classification system (Class A-D) impact your device's path to market? • What are the new Quality Management System requirements for manufacturers? • How has the licensing process changed, and what is the role of the India Authorized Agent? • What are your post-market surveillance and vigilance responsibilities under the current rules? • What specific updates were made in the June 2023 amendment? • Is your foreign manufacturing site subject to inspection by the CDSCO? • How do you navigate the SUGAM online portal for submissions? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide, including India. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

China's new electrical safety standard, GB 9706.1-2020, is now in effect, creating critical deadlines and new requirements for medical device manufacturers. This episode provides a detailed breakdown of the standard, outlining the key changes from the previous version, crucial implementation dates for new and existing products, and the significant impact on market access. We explore the new emphasis on risk management, essential performance, and what you need to do to ensure your devices remain compliant in one of the world's largest medical device markets. Key Questions: • What is the GB 9706.1-2020 standard and why is it critical for my device? • When is the final deadline for my existing products to comply? • How does the new standard differ from the old GB 9706.1-2007 version? • What are the new requirements for "essential performance" and risk management? • What happens if my device isn't compliant by the deadline? • How do I find a qualified testing lab in China? • What are the first steps I should take to begin the transition? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode unpacks South Korea's pioneering Digital Medical Products Act (DMPA), set to revolutionize the regulatory landscape in January 2025. We explore the act's core components, including its new classification system for digital therapeutics and AI-driven software, the tailored approval processes, and what these changes mean for manufacturers seeking market access. Key Questions: • What is South Korea's new Digital Medical Products Act (DMPA)? • Why is it considered the first comprehensive law of its kind globally? • How does the DMPA classify different types of digital health products like AI and DTx? • What new approval pathways will manufacturers need to navigate starting in 2025? • How does the act support innovation for software-based medical devices? • Are there different enforcement dates for different parts of the regulation? • How does this new framework compare to regulations in the EU and the US? • What immediate steps should your company take to prepare for this change? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode provides a comprehensive overview of Australia's medical device regulations, governed by the Therapeutic Goods Administration (TGA). We explore the Therapeutic Goods (Medical Devices) Regulations 2002, detailing the risk-based classification system, the mandatory Essential Principles for safety and performance, the conformity assessment process, and the critical role of the Australian Register of Therapeutic Goods (ARTG) for market entry. Key Questions: • What is the TGA and what is its role in regulating medical devices in Australia? • How does the Therapeutic Goods (Medical Devices) Regulations 2002 impact market entry? • What are the different risk classifications for medical devices and why do they matter? • What are the 'Essential Principles' that every device must meet for TGA approval? • How do conformity assessment procedures differ for low-risk versus high-risk devices? • What is the ARTG and why is it critical for selling your device in Australia? • What are a manufacturer's post-market responsibilities after a device is approved? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode unpacks the crucial updates in Mexico's NOM-241-SSA1-2021, the mandatory standard for Good Manufacturing Practices for medical devices. We explore the enhanced Quality Management System (QMS) requirements, the formal inclusion of Software as a Medical Device (SaMD), and the significant decision by COFEPRIS to accept ISO 13485 and MDSAP certifications from foreign manufacturers, streamlining market access. Key Questions: • What is NOM-241-SSA1-2021 and when did it become mandatory for medical device manufacturers? • How does the new standard change the definition of a medical device in Mexico? • What are the core components of the newly emphasized Quality Management System? • Does COFEPRIS now officially recognize ISO 13485 and MDSAP for GMP compliance? • What does the update mean for software as a medical device (SaMD) manufacturers? • How can foreign manufacturers streamline their path to compliance in Mexico? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode demystifies Argentina's medical device registration process under the national regulatory body, ANMAT. We provide a detailed breakdown of the essential framework established by Disposition 9688 of 2019, covering everything from risk classification and registration pathways to the critical requirements for foreign manufacturers seeking market entry. Key Questions: • What is ANMAT Disposition 9688/2019 and why is it essential for MedTech manufacturers? • How does Argentina classify medical devices based on risk? • What are the different registration pathways for Class I, II, III, and IV devices? • Is it mandatory to appoint an Argentina Authorized Representative (AAR)? • What are the Spanish language requirements for technical documentation? • How long is a medical device registration valid in Argentina? • Can an MDSAP certificate simplify my quality system compliance with ANMAT? • What are the Good Manufacturing Practice (GMP) requirements for Argentina? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode unpacks Brazil's landmark medical device regulation, RDC 751/2022. We explore the key updates that align Brazil with global standards, including the new risk classification rules, the shift to an IMDRF-based Technical Dossier, and critical transition deadlines for manufacturers. Key Questions: • What major changes does RDC 751/2022 introduce for MedTech companies? • How do the new risk classification rules compare to the EU MDR? • What is the "Table of Contents" format, and how does it affect your technical file? • Did you meet the crucial February 29, 2024, deadline for up-classified devices? • Are there new provisions for Software as a Medical Device (SaMD)? • What are the updated labeling and Instructions for Use (IFU) requirements? • How do the Notificação and Registro pathways differ under the new resolution? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode provides a comprehensive guide to Colombia's medical device regulations, focusing on the foundational Decree 4725 of 2005 and the role of the regulatory body, INVIMA. We explore the four-tiered risk classification system, the detailed registration process for different device classes, the critical requirement of appointing a local representative, and the importance of post-market surveillance through the Tecnovigilancia program. Key Questions: • What is the foundational law for medical devices in Colombia and which agency enforces it? • How does Colombia's risk classification system for medical devices compare to the EU's? • Is a local representative in Colombia required to register a medical device? • Can approval in the EU or US help speed up registration with INVIMA? • For how long is a medical device registration valid in Colombia? • Who should be the legal owner of the registration – the manufacturer or the distributor? • What are the post-market surveillance requirements, known as Tecnovigilancia? • In what language must all registration documents be submitted to INVIMA? • Have there been any recent updates to the original 2005 decree? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

This episode provides a dense overview of the EU Medical Device Regulation (MDR 2017/745), a pivotal shift in European MedTech compliance. We explore the regulation's core pillars, from its emphasis on a total product lifecycle approach and stricter clinical data requirements to the challenges of device reclassification, the Notified Body bottleneck, and new transparency measures like EUDAMED and the UDI system. It’s a crucial guide for any manufacturer navigating this complex landscape. • What is the primary goal of Regulation (EU) 2017/745, the EU MDR? • How does the MDR shift focus from pre-approval to a total lifecycle approach? • Why are the new clinical evidence and Clinical Evaluation Report (CER) requirements so challenging? • What is the "Notified Body bottleneck" and how does it impact market entry timelines? • Are you aware of the extended transition deadlines and the critical dates from 2024? • What roles do the EUDAMED database and UDI system play in the new framework? • How does the MDR affect device classification and supply chain management? • Does your organization have a designated Person Responsible for Regulatory Compliance (PRRC)? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.

The European Union's In Vitro Diagnostic Regulation (IVDR) has replaced the IVDD, introducing a stricter, risk-based classification system and increasing Notified Body oversight for most devices. This episode breaks down the fundamental changes, the expanded scope that now includes software and genetic tests, and the critical extended transition deadlines established in July 2024, providing manufacturers with a clear roadmap for compliance. • What is the EU IVDR and how does it differ from the previous IVDD? • What are the new risk classifications (A, B, C, D) for IVDs? • How has the role of Notified Bodies changed under the new regulation? • What are the latest extended transition deadlines for high, moderate, and low-risk IVDs? • Are all IVD devices eligible for these extended deadlines? • What are the specific conditions for a legacy device to qualify for the transition period? • How does the IVDR affect medical device software and companion diagnostics? • What happens if a manufacturer’s IVDD certificate expired before the new extension? Ready to turn these insights into your competitive edge? Pure Global’s regulatory experts guide MedTech companies through every step of 30+ markets worldwide. Explore how we can accelerate your market entry at https://pureglobal.com or email [email protected] for tailored support.